Compare TTEC & EQ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TTEC | EQ |
|---|---|---|
| Founded | 1982 | 2017 |
| Country | United States | United States |
| Employees | 69400 | N/A |
| Industry | Retail: Computer Software & Peripheral Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 128.5M | 129.0M |
| IPO Year | 1996 | 2018 |
| Metric | TTEC | EQ |
|---|---|---|
| Price | $2.20 | $2.97 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 3 |
| Target Price | N/A | ★ $8.00 |
| AVG Volume (30 Days) | 779.4K | ★ 845.0K |
| Earning Date | 05-07-2026 | 05-25-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 40.80 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,509,171,000.00 | $41,095,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $0.10 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 2.15 | N/A |
| 52 Week Low | $1.91 | $0.29 |
| 52 Week High | $5.51 | $3.54 |
| Indicator | TTEC | EQ |
|---|---|---|
| Relative Strength Index (RSI) | 44.18 | 52.86 |
| Support Level | $2.12 | $1.68 |
| Resistance Level | $2.58 | $3.15 |
| Average True Range (ATR) | 0.15 | 0.26 |
| MACD | 0.01 | -0.01 |
| Stochastic Oscillator | 41.05 | 26.41 |
TTEC Holdings Inc provides customer engagement management tools and services. The company operates through two operating segment, TTEC Digital and TTEC Engage. TTEC Digital is engaged in building and implementing cloud-based and on-premises customer experience tools that enable clients to develop customer engagement strategies. TTEC Engage focuses on delivering sales and marketing solutions to help clients boost their revenue as well as on managing customer's front-to-back office processes to optimize the customer experience. TTEC Engage contributes the vast majority of the company's revenue, and its revenues are derived from the United States and Canada, followed by Philippines, Asia-Pacific and India.
Equillium Inc is a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders with the mission to develop life-changing therapeutics for patients. It primary goal is to advance EQ504, a novel aryl hydrocarbon receptor, or AhR, modulator, into and through clinical development. The Company operates through a single operating and reportable segment focused on the business of developing novel therapies to treat severe autoimmune and inflammatory disorders, with the mission to develop life-changing therapeutics for patients. The Company manages all business activities on a consolidated basis.